{{Drugbox
| verifiedrevid = 444178004
| IUPAC_name = 5-(Phenylcarbamoylimino)-3-(1-phenylpropan-2-yl)-5''H''-1,2,3-oxadiazol-3-ium-2-ide
| image = Sidnocarb.svg
| width = 260

<!--Clinical data-->
| tradename =  
| legal_CA = Schedule III
| legal_UK = Class C
| legal_DE = Anlage II
| legal_status = 
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| metabolism = hepatic
| elimination_half-life =  
| excretion = renal

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 34262-84-5
| ATC_prefix = none
| PubChem = 71932
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 16736988
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = UMT8MP2NDU

<!--Chemical data-->
| C=18 | H=18 | N=4 | O=2 
| molecular_weight = 322.36 g/mol
| smiles = O=C(\N=C1/C=[N+](\[N-]O1)C(C)Cc2ccccc2)Nc3ccccc3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H18N4O2/c1-14(12-15-8-4-2-5-9-15)22-13-17(24-21-22)20-18(23)19-16-10-6-3-7-11-16/h2-11,13-14H,12H2,1H3,(H,19,23)/b20-17+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = DMHQLXUFCQSQQQ-LVZFUZTISA-N
}}

'''Mesocarb''' (brand names '''Sidnocarb''', '''Sydnocarb''') is a [[stimulant]] [[drug]] which was developed in the [[USSR]] in the 1970s.<ref>GB Patent 1262830 - NOVEL SYDNONIMINE DERIVATIVE</ref><ref>{{cite journal |author1=Anokhina IP |author2=Zabrodin GD |author3=Svirinovskiĭ IaE |title=[Характеристика центрального действия сиднокарба] |language=Russian |journal=Zh Nevropatol Psikhiatr Im S S Korsakova |volume=74 |issue=4 |pages=594–602 |year=1974 |pmid=4825943 |trans_title=Characteristics of the central action of sidnocarb |issn=1997-7298}}</ref> It has been found to act as a selective [[dopamine reuptake inhibitor]],<ref name="pmid7312716">{{cite journal | vauthors = Erdö SL, Kiss B, Rosdy B | title = Inhibition of dopamine uptake by a new psychostimulant mesocarb (Sydnocarb) | journal = Pol J Pharmacol Pharm | volume = 33 | issue = 2 | pages = 141–7 | year = 1981 | pmid = 7312716 | doi = | url = }}</ref><ref>{{cite journal |doi=10.1111/j.1749-6632.2000.tb05191.x |vauthors=Anderzhanova EA, Afanas'ev II, Kudrin VS, Rayevsky KS |title=Effect of d-amphetamine and sydnocarb on the extracellular level of dopamine, 3,4-dihydroxyphenylacetic acid, and hydroxyl radicals generation in rat striatum |journal=Ann N Y Acad Sci |volume=914 |pages=137–45 |date=September 2000|pmid=11085316 |url=http://www.blackwell-synergy.com/openurl?genre=article&sid=nlm:pubmed&issn=0077-8923&date=2000&volume=914&spage=137}}</ref><ref>{{cite journal |vauthors=Gainetdinov RR, Sotnikova TD, Grekhova TV, Rayevsky KS |title=Effects of a psychostimulant drug sydnocarb on rat brain dopaminergic transmission in vivo |journal=Eur J Pharmacol. |volume=340 |issue=1 |pages=53–8 |date=December 1997|pmid=9527506 |url=http://linkinghub.elsevier.com/retrieve/pii/S0014-2999(97)01407-6 |doi=10.1016/S0014-2999(97)01407-6}}</ref> and is less potent and slower-acting but longer-lasting than [[dextroamphetamine]].<ref>{{cite journal |vauthors=Afanas'ev II, Anderzhanova EA, Kudrin VS, Rayevsky KS |title=Effects of amphetamine and sydnocarb on dopamine release and free radical generation in rat striatum |journal=Pharmacol Biochem Behav. |volume=69 |issue=3–4 |pages=653–8 |year=2001 |pmid=11509228 |url=http://linkinghub.elsevier.com/retrieve/pii/S0091-3057(01)00574-3 |doi=10.1016/S0091-3057(01)00574-3}}</ref>

Mesocarb was used for a variety of applications;<ref>{{cite journal  |vauthors=Witkin JM, Savtchenko N, Mashkovsky M, etal |title=Behavioral, toxic, and neurochemical effects of sydnocarb, a novel psychomotor stimulant: comparisons with methamphetamine |journal=J Pharmacol Exp Ther. |volume=288 |issue=3 |pages=1298–310 |date=1 March 1999|pmid=10027871 |url=http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=10027871 }}</ref> these include counteracting the sedative effects of [[benzodiazepine]] drugs,<ref>{{cite journal |vauthors=Valueva LN, Tozhanova NM |title=[Коррекция мезокарбом побочного действия транквилизаторов бензодиазепинового ряда] |language=Russian |journal=Zh Nevropatol Psikhiatr Im S S Korsakova |volume=82 |issue=8 |pages=92–7 |year=1982 |pmid=6127851 |trans_title=Sidnocarb correction of the adverse effects of benzodiazepine tranquilizers}}</ref> increasing workload capacity and cardiovascular function,<ref>{{cite journal |vauthors=Vinar O, Klein DF, Potter WZ, Gause EM |title=A survey of psychotropic medications not available in the United States |journal=Neuropsychopharmacology |volume=5 |issue=4 |pages=201–17 |date=December 1991|pmid=1804161 }}</ref> treatment of [[ADHD]] and hyperactivity in children,<ref>{{cite journal |author1=Turova NF |author2=Misionzhnik EIu |author3=Ermolina LA |author4=Aziavchik AV |author5=Krasov VA |title=[Экскреция моноаминов, их предшественников и метаболитов при гиперактивном синдроме у детей с интеллектуальной недостаточностью] |language=Russian |journal=Vopr Med Khim. |volume=34 |issue=1 |pages=47–50 |year=1988 |pmid=3369126 |trans_title=Excretion of monoamines, their precursors and metabolites in the hyperactivity syndrome in mentally defective children }}</ref><ref>{{cite journal |author=Krasov VA |title=[Лечение мезокарбом детей младшего школьного возраста с гипердинамическим синдромом] |language=Russian |journal=Zh Nevropatol Psikhiatr Im S S Korsakova |volume=88 |issue=8 |pages=97–101 |year=1988 |pmid=3195293 |trans_title=Sidnocarb treatment of young schoolchildren with the hyperdynamic syndrome }}</ref> as a [[nootropic]],<ref>{{cite journal |author1=Ganiev MM |author2=Kharlamov AN |author3=Raevskiĭ KS |author4=Guseĭnov DIa |title=[Effect of sidnocarb on learning and memory] |language=Russian |journal=Biull Eksp Biol Med |volume=104 |issue=10 |pages=453–4 |date=October 1987|pmid=3676468 |trans_title=Effect of sidnocarb on learning and memory }}</ref> and as a drug to enhance resistance to extremely cold temperatures.<ref>{{cite journal |vauthors=Barer AS, Lakota NG, Ostrovskaia GZ, Shashkov VS |title=[Фармакологическая коррекция холодовых воздействий на человека] |language=Russian |journal=Kosm Biol Aviakosm Med |volume=22 |issue=6 |pages=66–73 |date=Nov–Dec 1988 |pmid=2906380 |trans_title=Pharmacologic correction of the effect of cold on man }}</ref><ref>{{cite journal |vauthors=Levina MN, Badyshtov BA, Gan'shina TS |title=[Thermoprotector properties of a combination of sydnocarb with ladasten] |language=Russian |journal=Eksp Klin Farmakol |volume=69 |issue=1 |pages=71–3 |year=2006 |pmid=16579065 |trans_title=Thermoprotector properties of a combination of sydnocarb with ladasten }}</ref> It is also listed as having [[antidepressant]] and [[anticonvulsant]] properties.

Mesocarb was sold in [[Russia]] as 5 milligram tablets under the brand name '''Sydnocarb'''. Hydroxylated metabolites can be detected in urine for up to 10 days after consumption.<ref name="pmid15808002">{{cite journal | vauthors = Shpak AV, Appolonova SA, Semenov VA | title = Validation of liquid chromatography-electrospray ionization ion trap mass spectrometry method for the determination of mesocarb in human plasma and urine | journal = J Chromatogr Sci | volume = 43 | issue = 1 | pages = 11–21 | year = 2005 | pmid = 15808002 | doi = 10.1093/chromsci/43.1.11| url = }}</ref>

Mesocarb is almost unknown in the western world and is neither used in medicine or studied scientifically to any great extent outside Russia and other countries in the former Soviet Union. It has however been added to the list of drugs under international control and is illegal in most countries, despite its multiple therapeutic applications and reported lack of significant [[abuse potential]].<ref>{{cite journal |vauthors=Rudenko GM, Altshuler RA |title=[Experimental and clinical study of Sydnocarb] |language=Russian |journal=Hung Pharmacotherapy |volume=124 |issue= |pages=150–4 |year=1978}}</ref>

Mesocarb has been referred to as a [[prodrug]] of [[amphetamine]].<ref name="DettmeyerVerhoff2013">{{cite book|author1=Reinhard Dettmeyer|author2=Marcel A. Verhoff|author3=Harald F. Schütz|title=Forensic Medicine: Fundamentals and Perspectives|url=https://books.google.com/books?id=yHHABAAAQBAJ&pg=PA519|date=9 October 2013|publisher=Springer Science & Business Media|isbn=978-3-642-38818-7|pages=519–}}</ref> Indeed, it produces amphetamine as a [[metabolite]],<ref name="PolgárVereczkey1979">{{cite journal|last1=Polgár|first1=M.|last2=Vereczkey|first2=L.|last3=Szporny|first3=L.|last4=Czira|first4=G.|last5=Tamás|first5=J.|last6=Gács-Baitz|first6=E.|last7=Holly|first7=S.|title=Metabolism of mesocarb in the rat|journal=Xenobiotica|volume=9|issue=8|year=1979|pages=511–519|issn=0049-8254|doi=10.3109/00498257909087265}}</ref> and amphetamine concentrations are far higher than mesocarb concentrations in human urine 22 hours post-administration (0.7–186&nbsp;ng/mL and 0.004–0.17&nbsp;ng/mL, respectively).<ref name="pmid15808002" /> However, mesocarb also possesses molecular actions of its own, inhibiting the reuptake of dopamine and to a far lesser extent of [[norepinephrine]], but not of [[serotonin]].<ref name="pmid7312716" />

==Chemistry==
Mesocarb is a [[mesoionic]] [[sydnone imine]]. It has the amphetamine-backbone present, except that the ''R''<sub>N</sub> has a complicated imine side-chain present.

==Preparation==
[[File:Mesocarb synthesis.svg|600px|Mesocarb from feprosidnine.]]

==References==
{{Reflist|2}}

{{Stimulants}}
{{ADHD pharmacotherapies}}
{{Monoamine reuptake inhibitors}}

[[Category:Dopamine reuptake inhibitors]]
[[Category:Oxadiazoles]]
[[Category:Prodrugs]]
[[Category:Russian drugs]]
[[Category:Stimulants]]
[[Category:Ureas]]
[[Category:Drugs in the Soviet Union]]